Exact Therapeutics AS Cash Flow Conversion Efficiency

Latest as of December 2024: -0.697x

Exact Therapeutics AS cash flow conversion efficiency. Based on the latest financial reports, Exact Therapeutics AS (EXTX) has a cash flow conversion efficiency ratio of -0.697x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-80.55 Million ≈ $-8.48 Million USD) by net assets (Nkr115.55 Million ≈ $12.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Exact Therapeutics AS stock valuation for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Exact Therapeutics AS (2017–2024)

Cash flow conversion efficiency of Exact Therapeutics AS from 2017 to 2024. This chart illustrates how Exact Therapeutics AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Exact Therapeutics AS (EXTX) stock price for real-time trading data and today's change.

Exact Therapeutics AS Cash Flow Conversion Ratio Explained

Exact Therapeutics AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Exact Therapeutics AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Exact Therapeutics AS ranked by their cash flow conversion efficiency. Review Exact Therapeutics AS (EXTX) flexibility index to assess the company's free cash flow relative to its total liabilities.

Company	Cash Flow Conversion Efficiency
Craneware Plc LSE:CRW	0.008x
Suvidhaa Infoserve Limited NSE:SUVIDHAA	-0.075x
Imunon Inc NASDAQ:IMNN	-952.715x
Trajano Iberia Socimi SA MC:YTRA	0.005x
mTouche Technology Bhd KLSE:0092	-0.178x
Zelira Therapeutics Ltd AU:ZLD	0.530x
Koba Resources Ltd AU:KOB	N/A
Ranplan Group ST:RPLAN	16.007x

Annual Cash Flow Conversion Efficiency for Exact Therapeutics AS (2017–2024)

The table below shows the annual cash flow conversion efficiency of Exact Therapeutics AS from 2017 to 2024. Also see Exact Therapeutics AS balance sheet assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr115.55 Million ≈ $12.16 Million	Nkr-80.55 Million ≈ $-8.48 Million	-0.697x	+29.02%
2023-12-31	Nkr45.10 Million ≈ $4.75 Million	Nkr-44.30 Million ≈ $-4.66 Million	-0.982x	-88.90%
2022-12-31	Nkr65.11 Million ≈ $6.85 Million	Nkr-33.85 Million ≈ $-3.56 Million	-0.520x	+0.24%
2021-12-31	Nkr105.74 Million ≈ $11.13 Million	Nkr-55.11 Million ≈ $-5.80 Million	-0.521x	-220.16%
2020-12-31	Nkr159.65 Million ≈ $16.80 Million	Nkr-25.99 Million ≈ $-2.73 Million	-0.163x	+44.84%
2019-12-31	Nkr42.24 Million ≈ $4.44 Million	Nkr-12.46 Million ≈ $-1.31 Million	-0.295x	-35.10%
2018-12-31	Nkr57.06 Million ≈ $6.00 Million	Nkr-12.46 Million ≈ $-1.31 Million	-0.218x	+85.37%
2017-12-31	Nkr8.35 Million ≈ $878.27K	Nkr-12.46 Million ≈ $-1.31 Million	-1.493x	--

About Exact Therapeutics AS

OL:EXTX Norway Biotechnology

Market Cap

$4.66 Million

Nkr44.28 Million NOK

Market Cap Rank

#28684 Global

#257 in Norway

Share Price

Nkr0.70

Change (1 day)

+40.56%

52-Week Range

Nkr0.48 - Nkr2.70

All Time High

Nkr40.90